| Methods |
Study location not described.
Nine treatment cycles. |
| Participants |
Healthy women age 21 to 35 years with normal lipid levels and regular menses.
Excluded diseases affecting lipoprotein metabolism; recent OC, injectable hormones or certain drug use; certain diseases; high blood pressure; recent smoking; recent alcohol or drug abuse; pregnancy; lactation. |
| Interventions |
Desogestrel 50‐100‐150 µg and EE 35‐30‐30 µg (N=33) versus levonorgestrel 50‐75‐125 µg and EE 30‐40‐30 µg (N=34). |
| Outcomes |
Plasma lipids, glucose, insulin, hemostasis, sex hormone binding globulin. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No information |
| Allocation concealment (selection bias) |
Unclear risk |
No information |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
No information |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Early discontinuation and loss to follow up not reported.
One woman from desogestrel group excluded for protocol violation before starting treatment. |
